Dan Burgess is Chairman and CEO of Pulmocide and brings more than 30 years of experience in biotech corporate leadership. Dan was previously Founder, President, and CEO of Rempex Pharmaceuticals, Inc., an antibiotic company that was sold to the Medicines Company (now Novartis). Two antibiotics developed by Rempex have since been approved by the FDA. Prior to Rempex, he was President and CEO of Mpex Pharmaceuticals, Inc., a company that advanced an inhaled antibiotic for patients with cystic fibrosis into Phase 3 clinical trials before it was acquired by Aptalis (now AbbVie). The product was ultimately approved in Europe and Canada. He is also a Venture Partner with SV Health Investors, Chairman of the Joint Oversight Board of CARB-X, and chairman and/or a director of several public and private biotechnology companies.
Dan is a graduate of Stanford University (B.A., economics) and Harvard Business School (MBA).